Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data

Today, Cytokinetics Incorporated CYTK reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and statistically significant reductions in the average resting left ventricular outflow tract pressure gradient (LVOT-G) and the average post-Valsalva LVOT-G when compared to placebo.

Why It Matters: The new data is a needed win for the Company after Astellas Pharma Inc ALPMY and Amgen Inc AMGN have dropped partnerships with the Company this year.

Analyst Reaction: H.C. Wainwright analyst raised the price target to $53 from $41 and kept a Buy rating.

Analyst Joseph Pantginis is raising his projected chance of success for CK-274 to 65% from 50% and increasing his U.S. peak sales estimate. 

While meeting expectations around safety and efficacy, CK-274 also demonstrated a "differentiated and competitive clinical profile," Pantginis tells investors.

Needham also raised the price target to $48 from $33, with the Buy rating unchanged. 

Analyst Chad Messer notes that topline results from the Phase II study of CK-274 exceeded the necessary efficacy and titratability bars. 

The drug bested results from competitor mavacamten on both key measures of resting and Valsalva LVOT gradient. He points out that CK-274 could achieve these results more rapidly, with most patients reaching a steady titration in 6 weeks or less compared to 12 for mavacamten.

Mavacamten is the centerpiece of Bristol Myers Squibb & Co's BMY $13.1 billion buyout of MyoKardia, which is zeroing in on non-obstructive HCM and other indications.

Price Action: CYTK shares are up 44.1% at $27.70 during the market session on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetContractsSmall CapAnalyst RatingsGeneralheart diseasePhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!